Sign In
Buy RPRX
$53.57
+0.610 (+1.15%)
At Close: Jun 22, 2026
Goldman Sachs Predicts a Double-Digit Rally for These 2 Growth Stocks
12:15pm, Tuesday, 27'th Aug 2024
The tech stock selloff in July surprised the market but not those investors who were paying attention.
Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
03:04am, Thursday, 22'nd Aug 2024
Vertex franchise poses a significant downside risk. That said, Royalty Pharma has solid execution capabilities and is diversifying earnings with new investments. The company raised its 2024 outlook af
Royalty Pharma: Busy Putting Capital To Work
06:33pm, Sunday, 11'th Aug 2024
Royalty Pharma's stock has underperformed recently, down 7% year to date while the S&P500 has climbed 13%. In the company's latest Q2'24 results, Royalty Pharma reported a 12% increase in portfolio re
Royalty Pharma plc (RPRX) Q2 2024 Earnings Call Transcript
02:14pm, Thursday, 08'th Aug 2024
Royalty Pharma plc (NASDAQ:RPRX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head of Investor Relations and Communications
Royalty Pharma (RPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
12:30pm, Thursday, 08'th Aug 2024
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street es
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
09:35am, Thursday, 08'th Aug 2024
Royalty Pharma (RPRX) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.85 per share a year ago.
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q2 Earnings, Beyond Revenue and EPS
10:21am, Monday, 05'th Aug 2024
Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
11:05am, Thursday, 01'st Aug 2024
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
08:30am, Wednesday, 24'th Jul 2024
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital.
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Friday, 19'th Jul 2024
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
08:15am, Friday, 19'th Jul 2024
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S.
Royalty Pharma Declares Third Quarter 2024 Dividend
04:15pm, Wednesday, 17'th Jul 2024
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordina
Royalty Pharma (RPRX) Recently Broke Out Above the 50-Day Moving Average
10:31am, Wednesday, 17'th Jul 2024
From a technical perspective, Royalty Pharma (RPRX) is looking like an interesting pick, as it just reached a key level of support. RPRX recently overtook the 50-day moving average, and this suggests
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Monday, 15'th Jul 2024
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
06:00am, Wednesday, 26'th Jun 2024
I'm on the hunt for ‘Strong Buy' biotech stocks. According to Finviz.com, there are 680 U.S.-listed biotech stocks.
